| 11th week of 2013 patent applcation highlights part 35 |
| Patent application number | Title | Published |
|---|
| 20130064762 | METHODS OF DETECTING AND TREATING CANCERS USING AUTOANTIBODIES - This invention generally relates to a method of identifying pre-neoplastic or neoplastic tissue of a mammal by utilizing autoantibodies that detect the pre-neoplastic or neoplastic tissue. Also described herein are methods of killing pre-neoplastic or neoplastic tissue by either binding toxins to autoantibodies that detect the pre-neoplastic or neoplastic tissue or introducing toxin-conjugated molecules that can in turn recognize the autoantibodies already bound to the pre-neoplastic or neoplastic tissue. | 2013-03-14 |
| 20130064763 | ANTI-ICAM-1 SINGLE DOMAIN ANTIBODY AND USES THEREOF - Anti-ICAM-1 V | 2013-03-14 |
| 20130064764 | Miniaturized 62Zn/62Cu Generator for High Concentration Clinical Delivery of 62Cu Kit Formulation for the Facile Preparation of Radiolabeled Cu-BIS(Thiosemicarbazone) Compounds - A new system accomplishes easy, interchangeable production of multiple PET radiopharmaceuticals through the use of a simplified eluant-only generator and a kit based synthesis technique employing lyophilized or freeze dried ligand. Thus, by simply switching the lyophilized ligand vial kit, any number of | 2013-03-14 |
| 20130064765 | ANTITHROMBOTIC NANOPARTICLE - The present invention encompasses an antithrombotic nanoparticle. | 2013-03-14 |
| 20130064766 | TRICARBONYL TECHNETIUM-99m OR RHENIUM-188 LABELED CYCLIC RGD DERIVATIVES, A PREPARATION METHOD THEREOF, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES AS AN ACTIVE INGREDIENT FOR USE IN THE DIAGNOSIS OR TREATMENT OF ANGIOGENESIS-RELATED DISEASES - The present invention relates to tricarbonyl technetium-99m or rhenium-188 labeled cyclic RGD derivatives, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment (radiotherapy) of angiogenesis-related diseases. The tricarbonyl technetium-99m or rhenium-188 labeled cyclic RGD derivatives of the present invention has a high subnanomolar affinity to integrin α | 2013-03-14 |
| 20130064767 | IMAGING INFECTION WITH COMPOUNDS THAT BIND TO THYMIDINE KINASE - The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection. | 2013-03-14 |
| 20130064768 | LIPOPHILIC CATIONIC PROBE FOR PET-IMAGING - The present invention provides an imaging probe which comprises a lipophilic cation, a hydrophobic moiety and a PET nucleus. The present invention also provides a precursor molecule for the production of such an imaging probe and methods for using the probe for analysing mitochondrial membrane potential in a subject. | 2013-03-14 |
| 20130064769 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF - The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comprising a radioisotope (e.g., | 2013-03-14 |
| 20130064770 | RADIOLABELED COMPOUNDS AND METHODS THEREOF - The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders. | 2013-03-14 |
| 20130064771 | PHOTOACOUSTIC MATCHING MATERIAL - A photoacoustic matching material includes water, a thickener, and a light scattering member. | 2013-03-14 |
| 20130064772 | INFECTION ACTIVATED WOUND CARING COMPOSITIONS AND DEVICES - Provided are wound caring compositions and devices containing a pH-sensitive, preferably acid degradable, components contained in a water-permeable and hydronium ion permeable material. The pH-sensitive component encloses an antibiotic which is released to the wound upon infection by a microorganism at the wound site, and/or encloses a pH indicator. The antibiotic release is triggered by the microorganism's production of CO | 2013-03-14 |
| 20130064773 | DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF - The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention. | 2013-03-14 |
| 20130064774 | METHODS AND COMPOSITIONS FOR MAINTENANCE OF A FUNCTIONAL WOUND - The present invention relates to methods and compositions for the modulation of wound healing and/or the production of extracellular membrane components by modulating the activity and/or amount of secreted protein acidic and rich in cysteine (SPARC) protein. The invention further provides methods for identifying compounds useful in the above-mentioned methods and compositions. | 2013-03-14 |
| 20130064775 | USE OF RILUZOLE FOR TREATING OR PREVENTING THE ADVERSE EFFECTS OF ANTINEOPLASTIC AGENTS - This invention relates to riluzole for use in the treatment or prevention of adverse effects associated with the administration of anticancer agents having neurotoxic effects, such as, for example, platinum salts, taxanes and periwinkle alkaloids. | 2013-03-14 |
| 20130064776 | LABELLED SILICA-BASED NANOMATERIAL WITH ENHANCED PROPERTIES AND USES THEREOF - The present invention relates to labelled silica-based nanoparticles with enhanced properties, to process for preparing them and to uses thereof. | 2013-03-14 |
| 20130064777 | SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS THEIR USES - A substantially surface active agent free composition which includes a hydrophobic solvent, and/or a petrolatum, a paraffin wax and/or a fatty alcohol, a fatty acid and/or a wax and/or shea butter, with and without a propellant. A substantially surface active agent free composition, further comprising, a tetracycline antibiotic, or a vitamin D derivative, or one or more other active agents. A method of treatment using a substantially surface active agent free composition. | 2013-03-14 |
| 20130064778 | Oral hygiene products and method - The present invention is directed towards a composition for highly efficient and quick plaque and tartar removal and inhibition including pure ascorbic acid crystals and/or granulars (vitamin C) and an enamel repairing composition such as hydroxyapatite. The composition can contain from about 10% up to 90% of ascorbic acid without compromising the tooth enamel because hydroxyapatite will repair any damage to the enamel. The composition can be used as dental powder, toothpaste, mouthwash, mouth spray and chewing gum in order to cover a wide range of consumers in different settings. | 2013-03-14 |
| 20130064779 | ORAL CARE COMPOSITIONS RESISTANT TO MICROBIAL GROWTH - Described herein are compositions which prevent the growth of bacteria resistant to high salt concentrations, methods of preparing the same, and methods of using the same. | 2013-03-14 |
| 20130064780 | COMPOSITIONS COMPRISING AVERMECTIN/AZELAIC ACID COMPOUNDS USEFUL FOR TREATING E.G., ROSACEA - Pharmaceutical/dermatological compositions useful for the prevention/treatment of disorders of the skin, especially rosacea, contain thus effective amounts of at least one avermectin compound, e.g., ivermectin, and at least one azelaic acid compound or salt or derivative thereof, formulated into a physiologically acceptable medium therefor. | 2013-03-14 |
| 20130064781 | METHOD FOR MASKING THE BITTERNESS OF A UV-SCREENING AGENT - The subject of the invention is the use of a sweetener such as sucralose or an extract of | 2013-03-14 |
| 20130064782 | COSMETIC COMPOSITION COMPRISING A BITTER COMPOUND, A FRAGRANCE, AN EXTRACT OF STEVIA AND A SALT - The subject of the invention is the use of an extract of | 2013-03-14 |
| 20130064783 | BORON-CONTAINING SMALL MOLECULES - This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate. | 2013-03-14 |
| 20130064784 | Treatment Composition - A concentrated treatment composition includes a bird repelling composition, a glycol, and a fragrance-containing/odor control composition. The concentrated treatment composition provides a stable product that is miscible with water. Methods for applying to the treatment compositions are also provided. | 2013-03-14 |
| 20130064785 | SKIN TREATMENT COMPOSITION - The invention is in the field of skin hygiene, especially hand hygiene and/or hand soap compositions. It remains to be desired to prepare skin hygiene compositions having a high anti-microbial effect, even with a low dosage of anti-microbial essential oils. It is therefore an object of the invention to provide a skin hygiene composition, having good anti-microbial properties, at low levels of essential oil. Surprisingly it has been found that composition comprising a low amount of at least two essential oils and a polymer provides improved hygiene efficacy. | 2013-03-14 |
| 20130064786 | siRNA HYDROGEL AND METHOD FOR MANUFACTURING THE SAME - The present invention relates to siRNA hydrogel and a method for manufacturing the same, and more particularly, to siRNA hydrogel for targeted gene silencing, which is nano-structured for targeted gene silencing, and a method for manufacturing the same. | 2013-03-14 |
| 20130064787 | Methods for Treatment of HIV and Other Infections Using a T Cell or Viral Activator and Anti-Retroviral Combination Therapy - Disclosed is a method for treating infection with a pathogen. The method involves administration of: (1) a substance which induces active pathogen replication in a cell latently infected with HIV and (2) an anti-pathogen drug. Also disclosed are methods for expanding CD4+ T cells from peripheral blood mononuclear cells isolated from human subjects in the presence of an antiretroviral drug and for treating HIV infection by infusing the expanded CD4+ T cells into HIV-infected patients. | 2013-03-14 |
| 20130064788 | IL-17 FAMILY CYTOKINE COMPOSITIONS AND USES - Binding proteins, including non-naturally occurring and recombinantly modified proteins that bind to an IL-17R and including proteins having a mutated IL-17 cytokine sequence, methods of making such molecules and methods of using such molecules as therapeutic, prophylactic and diagnostic agents are provided. | 2013-03-14 |
| 20130064789 | Hairy Cell Leukemia Biomarkers and Methods of Using Same - The present invention relates to hairy cell leukemia biomarkers and methods of utilizing these biomarkers to diagnose and/or treat hairy cell leukemia. | 2013-03-14 |
| 20130064790 | PEPTIDES WITH THE CAPACITY TO BIND TO INTERLEUKIN-10 (IL-10) - The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions. | 2013-03-14 |
| 20130064791 | Interferon Analogs - The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor. | 2013-03-14 |
| 20130064792 | THERAPY FOR INFLUENZA LIKE ILLNESS - An agent selected from: (a) interferon-β (IFN-β); (b) an agent that increases IFN-β expression; or (c) a polynucleotide which is capable of expressing (a) or (b); for use in the treatment of individuals with lower respiratory tract illness that has developed during or following an established ILI, wherein said treatment is by airway delivery of said medicament. | 2013-03-14 |
| 20130064793 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS - Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. | 2013-03-14 |
| 20130064794 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections - Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. | 2013-03-14 |
| 20130064795 | IMMUNE MODULATION - The invention provides a layered double hydroxide compound for use in modulating an immune response to an antigen, and an immune modulator composition comprising the layered double hydroxide and an antigen. The compound is of formula (I), (II), or (III) | 2013-03-14 |
| 20130064796 | METHODS FOR THE PREVENTION AND CONTROL OF PATHOGENIC INFECTIONS IN BEES AND RELATIVE COMPOSITION - The invention relates to a probiotic mixture for the protection of bees' health, and more specifically for the protection from microbial pathologies, such as those caused by | 2013-03-14 |
| 20130064797 | COMPOSITION FOR MUCOSALLY DELIVERING FRUIT CELL CULTURES AND/OR PREPARATIONS DERIVED THEREFROM AND METHODS OF USING SAME - A pharmaceutical or nutraceutical composition comprising a cell line callus culture of grape berry cells grown in vitro, whereby the cell line callus culture of grape berry cells is derived from one or more of grape-berry cross section, grape-berry skin, grape-berry flesh, grape seed, grape embryo of seeded or seedless cultivars or grape seed coat. | 2013-03-14 |
| 20130064798 | METHODS AND COMPOSITIONS FOR TREATING CONGESTIVE HEART FAILURE - Compositions and methods for treating congestive heart failure are provided herein. | 2013-03-14 |
| 20130064799 | METHODS FOR PROMOTING CELL REPROGRAMMING - The present invention is based on the seminal discovery that several kinases play important roles in barrier pathways in somatic cell reprogramming. The present invention provides that modulating expression or activity of these kinases can significantly promote or enhance cell reprogramming efficiency. Key kinases are identified and key regulation networks involving such kinases are also identified that may be advantageously targeted to significantly increase reprogramming efficiency as well as direct differentiation of induced pluripotent stem (iPS) cells. | 2013-03-14 |
| 20130064800 | Tissue-Engineered Endothelial and Epithelial Implants Differentially and Synergistically Regulate Tissue Repair - Endothelial implants restore vascular homeostasis after injury without reconstituting vascular architecture. Endothelial cells line the vascular epithelium and underlying vasa vasorum precluding distinction between cellular controls. Unlike blood vessels, the airway epithelium is highly differentiated and distinct from endothelial cells that line the bronchial vasa allowing investigation of the differential control tissue engineered cells may provide in airways and blood vessels. Through airway injury and cell culture models, tissue engineered implants of the bronchial epithelium and endothelium were found to promote synergistic repair of the airway through biochemical regulation of the airway microenvironment. While epithelial cells modulate local tissue composition and reaction, endothelial cells preserve the epithelium; together their relative impact was enhanced suggesting both cell types act synergistically for airway repair. | 2013-03-14 |
| 20130064801 | Cellular Compositions and Methods of Making and Using Them - The invention relates to cellular compositions comprising hematopoietic cells with the potential or increased potential to form non-hematopoietic cells; methods for producing such cellular compositions; methods for differentiation of cells of cellular compositions of the invention into cells that exhibit morphological, physiological, functional, and/or immunological features of non-hematopoietic cells; and uses of the cellular compositions. The invention also relates to a method for the expansion of hematopoietic stem and progenitor cells. | 2013-03-14 |
| 20130064802 | METHODS, COMPOSITIONS, AND ASSAYS FOR DETERMINING THE EFFECT OF AN IMMUNE CELL ON A CELL FROM AN INFECTIOUS OR NEOPLASTIC DISEASE - An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. Also provided is an in vitro assay for determining the effect of an activated CD8 | 2013-03-14 |
| 20130064803 | BIO-REPLENISHMENT (BioRep) FOR COGNITIVE HEALTH - Methods to prepare a bio-replenishment (BioRep) with specific combinations of S-adenosylmethionine (SAMe), lactoferrin (LF) and ribonuclease (RNAse) to restore cognitive health are disclosed. These methods have implications in the clinical management of cognitive afflictions such as anxiety, dementia and depression. | 2013-03-14 |
| 20130064804 | BIO-REPLENISHMENT (BioRep) FOR IMPROVING SLEEP ARCHITECTURE - Methods to prepare a bio-replenishment (BioRep) with specific combinations of S-adenosylmethionine (SAMe), lactoferrin (LF) and ribonuclease (RNAse) to restore regular sleep pattern are described. Additionally, compositions of functional delivery systems that recreate both alternate phases of non-rapid eye movement (NREM) and rapid eye movement (REM) sleep cycles are disclosed. These methods and compositions have implications in the clinical management of various sleep disorders including insomnia, circadian rhythm disorders and obstructive sleep apnea. | 2013-03-14 |
| 20130064805 | HIGHLY FUNCTIONAL ENZYME HAVING ALPHA-GALACTOSIDASE ACTIVITY - The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired α-galactosidase activity by changing the structure of the active site of wild-type human α-N-acetylgalactosaminidase. | 2013-03-14 |
| 20130064806 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR - The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I. | 2013-03-14 |
| 20130064807 | USE OF THROMBIN MUTANTS TO INHIBIT THE ANTICOAGULATION EFFECT OF THROMBIN INHIBITORS - The present disclosure provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present disclosure include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent. In one embodiment, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered. The present disclosure further provides a method for quantifying the concentration of an anticoagulant in the plasma or whole blood of a patient using a variant prothrombin or thrombin titration assay. | 2013-03-14 |
| 20130064808 | Biologically Active Oils - A process for the production of fats or oils and their extracts containing biologically active chemical compounds from a lipid substrate, the process comprising: a) inoculation of a lipid substrate with fungally derived lipolytic enzymes; b) incubating the inoculated substrate for a period of between about 7-120 days at a temperature of between about 4-35° C., at a humidity of between about 75-100%, and c) processing said substrate mixture to obtain a biologically active fat or oil. | 2013-03-14 |
| 20130064809 | Antimicrobial Composition and Uses Thereof - A composition for prophylactic and/or therapeutic medicinal applications, or plant protection applications, in particular for the control of microorganisms, either planktonic or organized in biofilms. The composition includes at least one ion selected from hypohalite, at least one compound selected from lactoferrin, lactoferrin peptide, lysozyme, immunoglobulins or a combination thereof, optionally hypothiocyanite, and optionally at least one growth factor. | 2013-03-14 |
| 20130064810 | Methods and Compositions for the Detection and Treatment of Cancer involving miRNAs and miRNA Inhibitors and Targets - The present invention relates to microRNAs (miRNAs) which are associated with cancer, particularly including hematologic malignancies, and particularly T-cell acute lymphoblastic leukemia (T-ALL), and to the assessment and modulation thereof in the treatment and management of cancer. The present invention is directed to methods and compositions for diagnosing and treating cancer, particularly T-ALL, by modulating miRNAs, and the use of miRNAs and antagonists thereof, particularly antagomirs, for predicting and assessing response to treatment, in assays for isolating and selecting antagists, and as compositions for the treatment and management of cancer. Methods and compositions are provided for treatment or alleviation of cancer, particularly T-ALL, with antagonists/antagomirs of miRNAs, particularly one or more of miR-19b, miR-20a, miR26, miR92, miR148 and miR223. | 2013-03-14 |
| 20130064811 | Methods to Enhance Cancer Treatment - Herein are provided methods for reducing or eliminating cancer in a patient in need of cancer treatment, by providing cholesterol deprivation therapy (CDT) in conjunction with antibodies directed against cholesterol-deprived tumor cells. Further provided are methods of enhancing the efficacy of other cancer treatments, by administering CDT and antibodies directed against cholesterol-deprived tumor cells, in combination with additional anti-cancer therapies. | 2013-03-14 |
| 20130064812 | COMBINATION THERAPIES FOR HEMATOLOGIC MALIGNANCIES - The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, | 2013-03-14 |
| 20130064813 | Protein Belonging to the TNF Superfamily Involved in Signal Transduction, Nucleic Acids Encoding Same and Methods of Use Thereof - A method of modulating immune response in an animal is disclosed. Such a method interacting the immature dendritic cells from the animal with an antigen ex vivo so that the immature dendritic cells present the antigen on their surfaces, inducing maturation of the immature dendritic cells ex vivo, and contacting the mature dendritic cells ex vivo with a modulator comprising TRANCE, conservative variants thereof, fragments thereof, analogs or derivatives thereof, or a fusion protein comprising the amino acid sequence of TRANCE, conservative variants thereof, or fragments thereof. After contacting the modulator ex vivo, the mature dendritic cells are introduced into the animal. As a result, immune response in the animal towards the antigen is modulated relative to the immune response against the antigen in an animal in which dendritic cells did not interact with the antigen ex vivo, and did not contact a modulator ex vivo. Preferably, the method of the present invention results in increasing immune response towards the antigen in the animal. | 2013-03-14 |
| 20130064814 | ANTAGONISTS OF PRODUCTS OF THE HS.459642 UNIGENE CLUSTER FOR THE INHIBITION OF PROLIFERATION, DEVELOPMENT OR DIFFERENTIATION OF STEM CELLS INCLUDING CANCER STEM CELLS - The present disclosure provides methods and compositions for inhibiting the proliferation, differentiation, or development of stem cells and cancer stem cells in a patient in need thereof. The methods involve administering to a patient a therapeutically effective amount of an antagonist of an Hs.459642 Unigene Cluster product, such as an inhibitor of CACNA1H. The compositions include an antagonist of an Hs.459642 Unigene Cluster product, such as an inhibitor of CACNA1H. Specific antagonists such as antibodies and antisense oligonucleotides, and combination therapy with one or more additional anti-cancer agents, are also provided by this disclosure. Such methods, antagonists, and compositions can be useful, for example, in the treatment of cancer. | 2013-03-14 |
| 20130064815 | INDUCING APOPTOSIS IN QUIESCENT CELLS - Compositions comprising an autophagy inhibitor and at least one of an NADPH modulator or a glutathione inhibitor are provided. Methods of inhibiting or killing a quiescent cell are provided. Methods of treating cancer are provided. Methods of identifying compositions that inhibit or kill quiescent cells are provided. Methods of identifying compositions that inhibit or kill quiescent cells are provided. Methods of inducing apoptosis are provided. Methods of sensitizing quiescent cells to proteasome inhibitors are provided. | 2013-03-14 |
| 20130064816 | TNF-alpha ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF TNF-MEDIATED DISEASE - Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation. | 2013-03-14 |
| 20130064817 | ENGINEERED ANTI-IL-23R ANTIBODIES - Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. | 2013-03-14 |
| 20130064818 | USE OF IMMUNESUPPRESSANT RECEPTOR - The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. | 2013-03-14 |
| 20130064819 | Biomarkers - The use of HLA-DQA1 as a biomarker for predicting or determining the therapeutic efficacy of anti-TNF therapy. | 2013-03-14 |
| 20130064820 | METHODS AND COMPOSITIONS FOR TREATING DEGOS' DISEASE - The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and/or an inhibitor of interferon alpha, and the use of the compositions in methods for treating or preventing Degos' disease in a subject. In some embodiments, the inhibitor is an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or to a biologically-active fragment of C5 such as C5a or C5b. In some embodiments, the inhibitor is an antibody, or an antigen-binding fragment thereof, that binds to interferon alpha or to an interferon alpha receptor. | 2013-03-14 |
| 20130064821 | METHODS AND COMPOSITIONS FOR TREATING PROSTATE CANCER - A polypeptide comprising an androgen binding region, the androgen binding region capable of binding to an androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available androgen is decreased. Specifically disclosed is an AR IgG1 Fc fusion protein, comprising the androgen binding domain of human androgen receptor and the Fc region of IgG. This fusion protein is used in the treatment of prostate cancer and testosterone flare. | 2013-03-14 |
| 20130064822 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 2013-03-14 |
| 20130064823 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) MULTIVALENT ANTIBODIES - The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding do mains for two different binding sites of LRP6 and compositions and methods of use thereof. | 2013-03-14 |
| 20130064824 | Combination pharmaceutical composition and methods of treating diabetes and metabolic disorders - The present application provides a pharmaceutical composition for administration to a patient suffering from diabetes and other metabolic disorders, the composition comprises a) an activated-potentiated form of an antibody to human insulin receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase. | 2013-03-14 |
| 20130064825 | METHODS OF TREATING OR PREVENTING CHOLESTEROL RELATED DISORDERS - The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described. | 2013-03-14 |
| 20130064826 | ANTI-EMR1 ANTIBODIES - The invention provides anti-EMR1 antibodies and methods of using such antibodies to treat EMR1-related diseases. | 2013-03-14 |
| 20130064827 | IL-17 HOMOLOGOUS POLYPEPTIDES AND THEREAPEUTIC USES THEREOF - The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 2013-03-14 |
| 20130064828 | Chimeric Vaccine for Haemophilus Influenzae-Induced Disease - The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention. | 2013-03-14 |
| 20130064829 | Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization - Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures. | 2013-03-14 |
| 20130064830 | Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization - Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures. | 2013-03-14 |
| 20130064831 | IMMUNOTHERAPEUTIC DOSING REGIMENS AND COMBINATIONS THEREOF - The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of immunotherapeutic agents e.g. CTLA-4 antagonists such as Ipilimumab or Tremelimumab in combination with one or more chemotherapeutic agents in cancer patients. | 2013-03-14 |
| 20130064832 | NOTCH INHIBITION IN THE TREATMENT AND PREVENTION OF A METABOLIC DISEASE OR DISORDER AND CARDIOVASCULAR COMPLICATIONS THEREOF - The present invention is directed to methods of treating or preventing a metabolic disease or disorder and cardiovascular complications and other complications thereof by administering agents that inhibit the NOTCH signaling pathway. In addition, the invention encompasses methods for determining whether a patient is at increased risk for developing these conditions by determining the amount, function, or activity of NOTCH pathway components in biological samples derived from the patient or in imaging analyses. | 2013-03-14 |
| 20130064833 | Monitoring and Modulating HGF/HGFR Activity - Provided are methods and compositions for the modulation of hepatocyte growth factor activity to regulate lymphatic vessel development and function. Methods and composition for the monitoring and treatment of skin disorders, lymphedema, and metastatic cancers are disclosed. Also described are methods of identifying inhibitors of hepatocyte growth factor dependent lymphangiogenesis. | 2013-03-14 |
| 20130064834 | METHODS FOR TREATING HYPERCHOLESTEROLEMIA USING ANTIBODIES TO PCSK9 - The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof. | 2013-03-14 |
| 20130064835 | RAGE REGULATES ROCK ACTIVITY IN CARDIOVASCULAR DISEASE - A method is provided for treating a RAGE-related disorder in a subject afflicted therewith comprising administering to the subject a therapeutically effective amount of an antagonist of rho-associated protein kinase 1 (ROCK1) so as to thereby treat the RAGE-related disorder. A method is also provided for treating a ROCK1-related disorder in a subject afflicted therewith comprising administering to the subject therapeutically effective amount of antagonist of receptor for advanced glycation end products (RAGE) so as to thereby treat the ROCK-related disorder. | 2013-03-14 |
| 20130064836 | Compositions and Methods for Antibodies Targeting Complement Protein C5 - The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof. | 2013-03-14 |
| 20130064837 | INTEGRIN ALPHA-V BETA8 NEUTRALIZING ANTIBODY - The present invention relates to ανβ8 antagonists, anti-ανβ8 antibodies or immunoconjugates for reducing TGFβ activation in an individual. Further provided are compositions comprising one of the ανβ8 antagonists, anti-ανβ8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter. | 2013-03-14 |
| 20130064838 | ENHANCED DEATH RECEPTOR AGONISTS - Methods and compositions for treatment of cancer in a human patient comprising administering a therapeutically effective amount of an Fc-polypeptide agonist of DR5 having high-affinity to FCGR3A. Methods of making the Fc-polypeptides are provided. | 2013-03-14 |
| 20130064839 | METHOD OF RAPIDLY PRODUCING IMPROVED VACCINES FOR ANIMALS - A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or fragment thereof, and administered to an animal which has been or is as risk of being exposed to the microorganism. A protective response to the biotype of the microorganism is obtained in the animal. | 2013-03-14 |
| 20130064840 | HJURP PEPTIDES AND VACCINES INCLUDING THE SAME - Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor. | 2013-03-14 |
| 20130064841 | IMMUNOGENIC COMPOSITIONS AGAINST HUMAN PROGASTRIN PEPTIDES - Immunogens against human extended-progastrin species comprise (A) a mimetic peptide comprised of (i) the amino acid sequence of a progastrin or a N- and/or C-terminal processed species of a progastrin joined to (ii) a 7 amino-acid spacer coupled to (B) an immunogenic carrier. Illustrative of the mimetic peptide/spacer combination are a 21 amino-acid peptide (SEQ ID NO.: 1) and other, related polypeptides (SEQ ID NOs.: 2-5). Pharmaceutical compositions containing such an immunogen display improved immunological properties, including the induction of effective antibody levels shortly after the administration of an initial course of immunogen. Levels of antibody thus elicited stay elevated for several months and readily elevate to higher levels upon subsequent boosting by a single injection of immunogen. | 2013-03-14 |
| 20130064842 | Compositions and Methods for Detection of Antibodies Specific for Anaplasma phagocytophilum (Aph) and Anaplasma platys (Apl) - The invention provides methods and compositions for the detection and treatment of | 2013-03-14 |
| 20130064843 | Identification of conserved peptide blocks in homologous polypeptides - Methods for identifying at least one conserved peptide block in three or more homologous polypeptides are provided and compositions comprising conserved peptides are provided. More particularly, methods for selecting conserved peptides in variable viral polypeptides for use in immunogenic compositions are provided. | 2013-03-14 |
| 20130064844 | NON-SPLICING VARIANTS OF GP350/220 - Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins. | 2013-03-14 |
| 20130064845 | BACTERIAL VACCINE COMPONENTS FROM STAPHYLOCOCCUS AUREUS AND USES THEREOF - Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the | 2013-03-14 |
| 20130064846 | NEISSERIAL ANTIGENS - The invention provides proteins from | 2013-03-14 |
| 20130064847 | Treatment and Composition for Achieving Skin Anti-Aging Benefits by Corneum Protease Activation - Novel methods and compositions for treating aged and environmentally damaged skin are disclosed which provide improvements in the skin's visual appearance, function and clinical/biophysical properties by activating at least one proteolytic enzyme in the skin's stratum corneum. The disclosed treatment methods involve topical application of a novel cosmetic composition containing a combination of a cationic surfactant such as N,N,-dimethyldodecyl amine oxide (DMDAO), an anionic surfactant such as sodium dodecyl sulfate (SDS), or monoalkyl phosphate (MAP) and a chelating agent such as ethylene diamine tetraacetate (EDTA) to stimulate a chronic increase in the replacement rate of the skin's stratum corneum by means of corneum protease activation. This chronic, low level stimulation is effective to induce repair and replacement of the stratum corneum, epidermis, and dermis of the skin and improvements in the appearance, function, and anti-aging properties of the skin. | 2013-03-14 |
| 20130064848 | HETEROCHAIN ALIPHATIC POLY-N-OXIDE COPOLYMERS AND VACCINATING AGENTS AND DRUGS BASED THEREON - Heterochain aliphatic poly-N-oxide copolymers of general formula (1), where R═N, CH; x=2 or 4; y=0 or 2; n=10-1000; q=(0.1-0.9)n; z=(0.1-0.9)n, exhibit pharmacological activity, including an antioxidant effect and a therapeutic effect as a detoxicant and immunomodulating agent. The copolymer may be used as vaccinating agent also comprising an antigen and a vaccine against hepatitis A and hepatitis B, which contains a vaccine preparation comprising HVA Ag and HBsAg simultaneously or vaccine preparations against hepatitis A and against hepatitis B. The invention represents a new class of compounds that exhibit a wide range of pharmacological activity and a vaccination effect as well as increased safety in use, and is directed towards increasing manufacturability, cost efficiency and environmental safety in the production of drugs. | 2013-03-14 |
| 20130064849 | METHODS TO TREAT AND PREVENT CARDIOVASCULAR DISEASE USING HUMAN PAPILLOMAVIRUS VACCINES - Embodiments of the invention include methods of treating or preventing cardiovascular disease, including atherosclerosis, myocardial infarction, and stroke, by administering an HPV vaccine, particular a vaccine that induces immunity against an oncogenic HPV type such as types 16 and 18. | 2013-03-14 |
| 20130064850 | Using Modified Plasmids to Suppress Antibiotic Resistant Pathogens - Methods of suppressing at least one species of micro-organism that is pathological to an organism. A first embodiment includes a method of suppressing at least one species of micro-organism that is pathological to an organism. A second embodiment includes a method of suppressing at least one species of micro-organism that is pathological to a mammal. A third embodiment includes a method of suppressing at least one species of bacteria that is pathological to a mammal. | 2013-03-14 |
| 20130064851 | INACTIVATED STAPHYLOCOCCAL WHOLE-CELL VACCINE - The vaccine that is protective against pathogenic bacterial species, typically staphylococcal species, and including methods to prepare said vaccine and to culture pathogenic bacteria. | 2013-03-14 |
| 20130064852 | VACCINE AGAINST MYCOPLASMA, HYOPNEUMONIAE, SUITABLE FOR ADMINISTRATION IN THE PRESENCE OF MATERNALLY DERIVED ANTIBODIES - The invention pertains to a vaccine comprising | 2013-03-14 |
| 20130064853 | PARASITE VACCINE - The present invention provides one or more antigens from the fourth stage (L4) larvae of non-blood feeding parasitic nematodes, for raising an immune responses in an animals, in particular bovines. The invention further provides methods of making immunogenic and/or vaccine compositions. | 2013-03-14 |
| 20130064854 | METHODS OF TREATING ALLERGIES WITH SUBSTANTIALLY PHENOL-FREE CARRIERS - A method for treating a patient suffering from allergy by desensitizing the patient to an allergen component that includes orally, sublingually, or intranasally administering to the patient a therapeutically effective amount of an immunomodulating composition and successively repeating the administration at a selected interval with the therapeutically effective amount of each successive administration comprising an increasing amount of the allergen component. The composition includes an amount of the allergen component that is sufficient to impart an immune response and a pharmaceutically acceptable carrier that is at least substantially free of phenol. The successive repeating occurs a sufficient number of times to reduce patient sensitivity to the allergen component, and avoids or minimizes oral adverse effects. An immunomodulating product is also described. | 2013-03-14 |
| 20130064855 | REPROGRAMMING IMMUNE ENVIRONMENT IN BREAST CANCER VIA DENDRITIC CELLS - Compositions and methods for the treatment of cancer disclosed herein. The method of the present invention comprises administration of compositions comprising β-glucan, a natural ligand for dectin-1, to block OX40L expression on tumor associated mDCs by blocking STAT6 phosphorylation. The β-glucan-treated mDCs secrete higher levels of IL-12p70 and do not expand TNFα and IL-13-producing CD4+ T cells, further resulting in inhibition of Th2 responses. Thus, compositions disclosed herein reprogram the function of mDCs in breast tumor microenvironment and turn tumor promoting Th2-type chronic inflammation into Th1-type acute inflammation that are able to reject tumors. The present invention finds particular uses for the intratumoral administration of the composition thereby directly binding to and directing a Th1-type acute inflammation. | 2013-03-14 |
| 20130064856 | UNIVERSAL TUMOR CELL VACCINE FOR ANTI CANCER THERAPEUTIC AND PROPHYLACTIC UTILIZATION - A universal vaccine containing a mixture of allogeneic cell lines, including tumor stem cells, effective against tumors regardless of type is disclosed. The cell lines are also modified to prevent interference with the immune response by any immunosuppressive agents they may secrete. | 2013-03-14 |
| 20130064857 | METHODS AND MATERIALS FOR MAKING AND USING VACCINES - This document relates to methods and materials for making and using vaccines. For example, vaccine preparations (e.g., whole cell vaccines and cell lysate vaccines) that can be used to treat cancer (e.g., human ovarian cancer) are provided. | 2013-03-14 |
| 20130064858 | POLYSACCHARIDE SUITABLE TO MODULATE IMMUNE RESPONSE - Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species | 2013-03-14 |
| 20130064859 | COMBINATORIAL VITAMIN D AND PROBIOTIC THERAPY FOR INFLAMMATORY BOWEL DISEASE - A method of increasing the percentage of mouse and human Tregs is provided comprising providing | 2013-03-14 |
| 20130064860 | Combination pharmaceutical composition and methods of theating genitourinary system disorders - The invention provides a pharmaceutical composition comprising a) an activated-potentiated form of an antibody to prostate-specific antigen, and b) an activated-potentiated form of an antibody to endothelial NO-synthase. Various embodiments and variants are provided. | 2013-03-14 |
| 20130064861 | COMPOSITIONS AND METHODS FOR MODIFYING IN VIVO CALCIFICATION OF HYDROGELS - Provided herein according to some embodiments of the invention are methods of inhibiting or preventing calcification of hydrogels. Such methods may include combining the hydrogel with a buffer solution having a pH lower than 7.4; forming a hydrogel by crosslinking alginate in a solution comprising a bisphosphonate compound; and/or forming a hydrogel by crosslinking a polyanionic polymer with a polyvalent cation that is not Ca | 2013-03-14 |
